Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model.
Sumit KumarMark J A SchoonderwoerdJessie S KroonenIlona J de GraafMarjolein SluijterDina RuanoRomán González-PrietoMatty Verlaan-de VriesJasper RipRamon ArensNoel F C C de MirandaLukas J A C HawinkelsThorbald van HallAlfred C O VertegaalPublished in: Gut (2022)
Our findings indicate that pharmacological inhibition of the SUMO pathway represents a potential strategy to target PDAC via a dual mechanism: inhibiting cancer cell cycle progression and activating anti-tumour immunity by inducing interferon signalling.